SAFETY AND ANTIVIRAL ACTIVITY OF MOTAVIZUMAB, A RESPIRATORY SYNCYTIAL VIRUS (RSV)–SPECIFIC HUMANIZED MONOCLONAL ANTIBODY, WHEN ADMINISTERED TO RSV-INFECTED CHILDREN

1 September 2009

journal article
research article
Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal

Vol. 28 (9) , 835-837
https://doi.org/10.1097/inf.0b013e3181a165e4

Abstract

Previously healthy children hospitalized with respiratory syncytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intravenously), an RSV-specific monoclonal antibody, or placebo. Safety, tolerability, motavizumab concentrations, and immunogenicity were assessed. Cultivatable RSV in the upper respiratory tract was significantly reduced with motavizumab compared with placebo day 1 post-treatment. No adverse events were considered motavizumab-related by site investigators.

Keywords

This publication has 14 references indexed in Scilit:

Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract
Journal of Molecular Biology, 2007
T Helper 1/T Helper 2 Cytokine Imbalance in Respiratory Syncytial Virus Infection Is Associated With Increased Endogenous Plasma Cortisol
Pediatrics, 2006
Respiratory Syncytial Virus Load Predicts Disease Severity in Previously Healthy Infants
The Journal of Infectious Diseases, 2005
Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: An experimental murine model
Virology Journal, 2005
Ultra-potent Antibodies Against Respiratory Syncytial Virus: Effects of Binding Kinetics and Binding Valence on Viral Neutralization
Journal of Molecular Biology, 2005
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
The Journal of Pediatrics, 2003
Type 1 and Type 2 Cytokine Imbalance in Acute Respiratory Syncytial Virus Bronchiolitis
American Journal of Respiratory and Critical Care Medicine, 2003
Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein
The Journal of Infectious Diseases, 1998
Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
Pediatrics, 1998
From the National Institute of Allergy and Infectious Diseases and the World Health Organization: Respiratory Syncytial and Parainfluenza Viruses
The Journal of Infectious Diseases, 1990